Detection of fluoroquinolone resistance in Mycobacterium tuberculosis clinical isolates as determined by gyrA/B gene mutation by using PCR technique  by Salah Eldin, A. et al.
Egyptian Journal of Chest Diseases and Tuberculosis (2012) 61, 349–353The Egyptian Society of Chest Diseases and Tuberculosis
Egyptian Journal of Chest Diseases and Tuberculosis
www.elsevier.com/locate/ejcdt
www.sciencedirect.comORIGINAL ARTICLEDetection of ﬂuoroquinolone resistance in Mycobacterium
tuberculosis clinical isolates as determined by gyrA/B
gene mutation by using PCR techniqueA. Salah Eldin a,*, N.M. Mostafa b, S.I. Mostafa ca Lecturer of Chest Department, Faculty of medicine, Beni-Suef University, Egypt
b Lecturer of Chest Department, Faculty of medicine, Cairo University, Egypt
c Lecturer of Clinical Pathology Department, Faculty of medicine, Beni-Suef University, EgyptReceived 1 August 2012; accepted 10 August 2012








gyrA and gyrB geneCorresponding author. Tel.:
mail address: Ab_salah1972@
er review under responsibil
iseases and Tuberculosis.
Production an
22-7638 ª 2013 The Egyptia





httpense.Abstract Fluoroquinolones are broad-spectrum antimicrobial agents that have been used with
increasing frequency over the past decade.
Fluoroquinolones have in vitro and in vivo activity against Mycobacterium tuberculosis.
However, resistance to ﬂuoroquinolones in cases of tuberculosis is not routinely assessed.
Mutations in a small region of gyrA, called quinolone resistance-determining region (QRDR)
and, less frequently, in gyrB are the primary mechanism of FQ resistance in M. tuberculosis.
PCR-based techniques provide new possibilities for the rapid diagnosis of ﬁrst- and second-line
drug resistance.
Results: There were 40 consecutive adults, who had culture conﬁrmed pulmonary tuberculosis
during the study period.
Mutations were observed in the QRDRs of both gyrA and gyrB in 22 isolates (55%). Only gyrA
+ve in 7(17.5%) isolates. Only gyrB +ve in 5(12.5%) isolates. Total gyrA +ve in 29(72.5%) and
total gyrB +ve in 28(70%) isolates. Both gyrA and gyrB ve in 6 (15%).
Conclusion: The incidence of FO-resistant M. tuberculosis is gradually increasing to alarming
levels this may be due to wide spread use of this vital groups of drugs in community-acquired pneu-
monia and urinary tract infections.
ª 2013 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier B.V.
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The World Health Organization (WHO) estimated that there
were 0.5 million cases of multi-drug resistant (MDR) tubercu-
losis (TB) in 2007. Only 8.5% of the estimated global total of
smear-positive cases of MDR–TB were notiﬁed. By the end of
2008, 55 countries and territories had reported at least one caseis. Production and hosting by Elsevier B.V.
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350 A. Salah Eldin et al.of extensively drug-resistant TB (XDR–TB) which are deﬁned
as MDR strains that are also resistant to a ﬂuoroquinolone
(FQ) and at least one second-line injectable agent (amikacin
(AM), Kanamycin (KM) and/or capreomycin (CM) [1].
Fluoroquinolones are broad-spectrum antimicrobial agents
that have been used with increasing frequency over the past
decade. The particular advantages of ﬂuoroquinolones are
their high bioavailability, convenient dosing intervals, and efﬁ-
cacy against a wide array of bacterial infections, including
community-acquired pneumonia [2,3].
Fluoroquinolones––in particular, levoﬂoxacin, gatiﬂoxacin,
and moxiﬂoxacin––have in vitro and in vivo activity against
Mycobacterium tuberculosis [4,5]. Fluoroquinolone resistance
in patients with newly diagnosed cases of tuberculosis would
be important if identiﬁed, because of the current role of ﬂuoro-
quinolones in the treatment of tuberculosis (i.e., treatment of
patients resistant to or intolerant of ﬁrst-line therapy) and
the potential of this class of drugs to become ﬁrst line therapy
[6,7].
However, resistance to ﬂuoroquinolones in cases of tuber-
culosis is not routinely assessed, particularly in isolates that
are susceptible to current ﬁrst-line agents.
Current Infectious Diseases Society of America/American
Thoracic Society guidelines for community acquired pneumo-
nia recommend that ﬂuoroquinolones be used for both inpa-
tient and outpatient treatment of pneumonia [8].
As a result, ﬂuoroquinolones are frequently prescribed to
people who are subsequently diagnosed with tuberculosis.
Among a cohort of patients with tuberculosis in Tennessee
from 2000 to 2004, 23% received ﬂuoroquinolone mono-
therapy before diagnosis. The proportion of exposed people in-
creased from 9% in 2000 to 41% in 2004 (P, 0.001) [9].
The cellular target of FQs in M. tuberculosis is DNA gyr-
ase, a type II topoisomerase consisting of two A and two B
subunits encoded by gyrA and gyrB genes, respectively [10].
Mutations in a small region of gyrA, called quinolone resis-
tance-determining region (QRDR) and, less frequently, in
gyrB are the primary mechanism of FQ resistance in M. tuber-
culosis [11,12].
Analysis of QRDR alone by genotypic tests has been sug-
gested as sufﬁcient for rapid identiﬁcation of vast majority of
FQ-resistant M. tuberculosis strains as additional target of
gyrB did not enhance the sensitivity signiﬁcantly [13,14].
Reports show that the majority (approximately 50–90%) of
FQ-resistant MTB isolates carry mutations in the quinolone
resistance-determining region (QRDR) of the gyrA gene [14],
and that a small number have mutations in the gyrB gene
[15,16]. It was previously postulated that efﬂux pump mecha-
nisms account for FQ resistance in isolates with wild-type gyr-
AB genes [17].
Fluoroquinolone resistance in M. tuberculosis can develop
after as little as 13 days of ﬂuoroquinolone therapy [10].
Although ﬂuoroquinolone resistance in M. tuberculosis is not
routinely assessed, the proportion of newly diagnosed (i.e.,
previously untreated patients with tuberculosis with ﬂuoro-
quinolone resistance has ranged from 0.15% to 3.6% in previ-
ous reports [18,19].
Extensive use of ﬂuoroquinolones for treatment of bacterial
infections might result in primary ﬂuoroquinolone-resistant
tuberculosis. If primary resistance became common, this would
negate the potential of ﬂuoroquinolones to become part of
ﬁrst-line tuberculosis treatment. PCR-based techniquesprovide new possibilities for the rapid diagnosis of ﬁrst- and
second-line drug resistance, however, not all mycobacterial
laboratories have access to DNA sequencing facilities [20].
Therefore, we evaluated the rate of ﬂuoroquinolone resis-
tance among M. tuberculosis isolates.
Materials and methods
Patient population
We conducted a cohort study of adult patients (age >18 years)
with sputum positive, culture conﬁrmed pulmonary tuberculo-
sis from both El Abassia & El Omrania Chest hospitals in the
period between September 2011 and February 2012. This study
was approved from ministry of health tuberculosis control
program.
Early-morning sputum specimens were collected and trans-
ported to the clinical laboratory for smear examination.
Detailed history taking was obtained from patients as re-
gards previous history of anti tuberculous treatment, recent
antibiotic used especially ﬂuroquinolone.
Sample collection & transport
The patient was instructed to cough deeply and expectorated
sputum specimens were collected from all patients in a
screw-cap, leak-proof sterile containers. Specimens were han-
dled with care as regards collection and transportation.Decontamination and concentration
The initial concentration of NaOH is 4%. This 4% NaOH
solution is mixed with an equal quantity of sodium citrate
solution (2.9%) to make a working solution (NaOH concen-
tration in this solution is 2%). When an equal quantity of
NaOH–NALC–citrate and sputum are mixed, the ﬁnal con-
centration of NaOH in the specimen is 1% [21]. Transfer the
specimen to a 50 ml centrifuge tube with a screw cap.
Add NaOH–NALC–sodium citrate solution in a volume
equal to the quantity of specimen. Tighten the cap.
Vortex lightly or hand mix for about 15–30 s. Invert the
tube so the whole tube is exposed to the NaOH–NALC
solution.
Wait 15–20 min (up to 25 min maximum) after adding the
NaOH–NALC solution. Vortex lightly or hand mix/invert
every 5–10 min or put the tubes on a shaker and shake lightly
during the whole time.
Make sure the specimen is completely liqueﬁed. If still mu-
coid, add a small quantity of NALC powder (30–35 g) directly
to the specimen tube. Mix well.
At the end of 15–20 min, add phosphate buffer (pH 6.8) up
to the top ring on the centrifuge tube (plastic tube has a ring
for 50 ml mark). Mix well (lightly vortex or invert several
times). Addition of sterile water is not a suitable alternative
for the phosphate buffer.
Centrifuge the specimen at a speed of 3000g or more for 15–
20 min. Use of refrigerated centrifugation at a higher speed is
known to increase recovery of mycobacteria 2, 62.
After centrifugation, allow tubes to sit for 5 min to allow
aerosols to settle. Then carefully decant the supernatant into
Figure 1 The above gel is for gyrA the (ladder) used is from 100,
200, 300, 400, 500, 600, 700, 800, 900, 1000 till 2000 and gyrA is at
216 bp, LAN 1 from the right side is for the marker (ladder), LAN
2–9, 11 and 12 are positive for gyraA, and the gel below is for
gyrB. gyrB is at 322 bp, the marker (ladder) used is from 100, 200,
300, 400, 500, 600, 700, 800, 900, 1000 till 2000 from the right side
LAN 1–6, 8 and 9 are positive for gyra B, LAN 10 is for the
ladder. (This photo is taken by gel documentation system).
Table 1 Clinical data of patients selected.
Sex 34 Male 6 Female
Age 18–72 years old Mean age 47.1
Cases 28 New cases (70%) 12 Relapse (30%)
Risk factors 9 Diabetics
4 addicts one on
steroids (IPF)
Table 2 Laboratory ﬁndings.
Zeil Neelsen for Sputum ve and MGIT ve 3
Zeil Neelsen for Sputum ve and MGIT +ve 1
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tant. Make sure the sediment is not lost during decanting of
the supernatant ﬂuid. Add a small quantity (1–2 ml) phosphate
buffer (pH 6.8) and resuspend the sediment with the help of a
pipette or vortex mixer.
Use the resuspended pellet for making smears and for inoc-
ulation of MGIT tubes [22]. Ziehl–Neelsen staining of M.
tuberculosis was done according to standards [23].
Culture
Culture was done using Mycobacteria Growth Index Test
(MGIT).[24].
Molecular detection of gyrA & gyrB was done according to
Soudani et al. [25].
DNA extraction
Colony was taken from MGIT Template DNA was prepared
by QIAGEN QIAmp DNA mini kit. Positive control was used
Escherichia coli, Staphylococcus aureus resistant to
ciproﬂoxacin.
Ampliﬁcation
Using Perkin Elmer 9700 for gyrA, a DNA fragment of
216 bp, corresponding to the QRDR, was generated by PCR
with the primer pair Pri9 (5¢-CGCCGGGTGCTCTATG-
CAATG-3¢) and Pri8 (5¢-CGGTGGGTCATTGCCTGGC-
GA-3¢), used at 4 lM. Ampliﬁcation reactions were
performed as previously described by [26]. For gyrB, a 322-
bp fragment was ampliﬁed using the primer pair gyrBA
(5¢-GAGTTGGTGCGCGCTAAGAGC-3¢) and gyrB E
(5¢-CGGCCATCAGCACGATCTTG-3¢) at 0.4 lM. Ampliﬁ-
cation reactions were performed as previously described by
Dauendorffer et al. [27].
Detection of (QRDR) by PCR
Ampliﬁed products were subjected to electrophoresis in 2%
agarose gels in Tris–borate–EDTA buffer and visualized under
UV light. The gyrA band was visualized at 216 bp and gyrB at
322 bp.Zeil Neelsen for Sputum +ve and MGIT +ve 34
Zeil Neelsen for Sputum +ve and MGIT ve 3
Only gyrA +ve 7(17.5%)
Only gyrB +ve 5(12.5%)
Both gyrA and gyrB +ve 22(55%)
Both gyrA and gyrB ve 6(15%)
gyrA +ve 29(72.5%)
gyrB+ve 28(70%)
Mutations were observed in the QRDRs of both gyrA and gyrB in
22 isolates (55%). Only gyrA +ve in 7(17.5%) isolates. Only gyrB
+ve in 5(12.5%) isolates. Total gyrA +ve in 29(72.5%) and total
gyr B +ve in 28(70%) isolates. Both gyrA and gyrB ve in 6(15%).Results
There were 40 consecutive adults, who had culture conﬁrmed
pulmonary tuberculosis during the study period.
Six Female (15%) & 34 (85%) males
Mean age 47.1 years (32–72 years)
Twenty eight (70%) newly diagnosed (patients were deemed
to have newly diagnosed tuberculosis if they had not received
standard antituberculosis treatment before developing culture-
conﬁrmed tuberculosis).
Twelve relapse (30%)
Twelve patients were associated with risk factors for lower
immunity (9 patients (22.5%) were diabetics, and 3 patients
(7.5%) were drug addict).
All cases had chest X-ray ﬁndings (inﬁltration, cavitation).
(See Fig. 1, Tables 1 and 2).Discussion
This study on ﬂuoroquinolone resistance among smear-posi-
tive pulmonary TB cases is the ﬁrst of its kind in Egypt.
352 A. Salah Eldin et al.Fluoroquinolones (FQs) are the most promising antituber-
culous therapeutic agents to be developed in 40 years [28].They
are widely used for the treatment of multidrug-resistant
(MDR) tuberculosis (TB) despite the lack of clinical trials eval-
uating optimal doses, duration, and combinations [29]. There
is concern about levels of preexisting FQ-resistant TB in re-
gions with high drug resistance rates because these drugs are
often available over the counter and are additionally pre-
scribed as broad-spectrum antibiotics for the treatment of
undiagnosed respiratory infections [30].
Mutations in short regions of gyrA, known as QRDR, have
been associated with FQ resistance inMTB [31]. Several studies
[32] have analyzed the mutations in the gyrA gene in clinical iso-
lates ofMTB.Most of these studies focused on the frequency of
the mutations in gyrA/gyrB genes in FQ-resistant MTB strains.
Thereare, however, no data on the association of mutations in
gyrA/gyrB and FQ resistance levels in MTB isolates.
Only Yin et al. have shown conclusively that different sub-
stitutions of amino acid 94 resulted in different levels of levo-
ﬂoxacin resistance [33].
Although the sample size in our study was substantially
small, the incidence of infection with ﬂuoroquinolone-resistant
M. tuberculosis appeared to be high. This may have been due
at least in part to increased use of ﬂuoroquinolones for the
treatment of lower respiratory tract infection. One rather
important mechanism for the development of ﬂuoroquino-
lone-resistant TB is the suboptimal use of second line drug reg-
imens, especially in the presence of a poorly functioning
program in the treatment of multidrug-resistant TB.
In our study 55% of the clinical isolates were positive for
both gyrA and gyrB, this agree with Yin and Yu [32] as they
detect 44 of 60 (73.3%) levoﬂoxacin-resistant MTB clinical iso-
lates, including 17 of 18 (94.4%) high-level resistant strains
and 27 of 42 (64.3%) low-level resistant strains, had mutation
in QRDR of gyrA gene.
The mutation patterns involved six patterns of single codon
mutation (H70R, A90V, S91A, D94G, D94A or D94N) and
one pattern of double codons mutation (A90V with D94A).
Of 60 levoﬂoxacin-resistant MTB clinical isolates, only one
(1.6%) mutated in gyrB gene (T511N) [31].
Also agree with Zhenling et al. [34]. Mutations were ob-
served in the QRDRs of gyrA/gyrB in 87 out of 95 (91.6%)
OFX-resistant MTB strains [34].
Mutations other than those affecting gyrA and other mech-
anisms could result in FQ-R, including: decreased cell-wall
permeability to drug, efﬂux pumps, drug sequestration or per-
haps even drug inactivation [35]. In a small number of cases,
FQ-R could be associated with gyrB mutations and a probable
efﬂux mechanism [36].
Our study was limited by the lack of the patients ﬂuroqui-
nolone exposure data. There is also natural polymorphism in
the nucleotide sequences of gyrA/gyrB, that is not associated
with drug resistance as natural polymorphism occur in both
ﬂuoroquinolone sensitive and resistant bacteria, so we recom-
mend performing DNA sequencing and concomitant drug sus-
ceptibility testing.Conclusion
The incidence of FO-resistant M. tuberculosis is gradually
increasing to alarming levels this may be due to wide spreaduse of this vital groups of drugs in community-acquired pneu-
monia and urinary tract infections.
Recommendations
We recommend judicious use of ﬂuoroquinolones as a broad
spectrum antibiotics and it is ideally to be reserved for treat-
ment of resistant TB or at least limit the use of prolonged or
repeated courses of FQ in patients at risk of having active TB.
We recommend further researches as DNA sequencing to
exclude natural polymorphisms and detect different kinds of
mutations affecting the genes. Also, recommend drug sensitiv-
ity testing to correlate the degree of resistance and drug inhibi-
tion with gene mutation and the possible methods to overcome
this problem.
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